#USA #San Francisco #Monoclonal Antibodies #Stämm #Bioreactor

A Game-Changer in Bioproduction: Stämm's Continuous Bioreactor

In a remarkable leap for biopharmaceuticals, Stämm has showcased the extraordinary effectiveness of its continuous laminar flow bioreactor, designed specifically for the production of monoclonal antibodies. With pilot projects successfully carried out in Germany, Switzerland, and Argentina, the results are nothing short of impressive, demonstrating a minimum increase of 15 times in volumetric productivity. This innovative technology is projected to multiply its output by as much as 50 times by 2025, revolutionizing the bioproduction landscape.

Breakthroughs in Efficiency and Cost-Effectiveness

The new bioprocessor, known as the Bioprocessor, is a plug-and-play desktop device that significantly reduces production costs when compared to traditional fed-batch systems. Operating efficiently under both adherent and suspension cultures, it mitigates downtime while maintaining consistent quality. Alongside impressive increases in product yield, the system achieves cell densities up to four times greater and specific productivity improvements.

As healthcare demands rise, particularly in the fields of oncology and chronic illnesses, Stämm is poised to meet consumer needs by facilitating the commercialization of biosimilars and various biologics. The production process benefits from a high surface-to-volume ratio and lower shear stress, which are critical for optimal results in cell and gene therapies.

An Integrated and Scalable Solution

Stämm’s bioreactor employs an innovative closed-system design utilizing 3D-printed single-use cartridges. This architecture not only allows for seamless scalability but also enhances cost-efficient operation. After successfully implementing pilot studies within a short span of less than three months, the Bioprocessor is now ready for global deployment, targeting underserved markets in need of advanced biomanufacturing capabilities.

The increased productivity is attributed to a homogeneous, stress-free environment created by the bioprocessor, ensuring optimal conditions including excellent gas exchange rates.

Setting New Standards in Bioproduction

As the biopharmaceutical industry approaches a patent cliff, Stämm sets itself apart as a critical partner capable of offering accessible and scalable bioproduction solutions. The innovative approach being pioneered by Stämm is anticipated to redefine standards in bioproduction, paving the way for the next generation of medications and fostering innovation in global biologic manufacturing.

About Stämm

Founded in 2016, Stämm has committed itself to transforming biologics production through the development of advanced automated bioprocessors. Their continuous, bubble-free production platform, utilizing cutting-edge 3D-printed bioreactors, not only boosts yields and cuts costs but also minimizes space and energy consumption. Striving to make bioproduction simple, scalable, and repeatable, Stämm’s solutions decentralize bioprocesses, allowing partners to focus on groundbreaking discoveries that can impact lives profoundly. For further details, visit Stämm’s website.